Recombinant human interleukin-6 accelerates in-virto megakaryocytopoiesis and platelet recovery post autologous peripheral blood stem cell transplantion

Arnon Nagler*, Vardar R. Deutsch, Gabor Varadi, Marjorie Pick, Amiram Eldor, Shimon Slavin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Prolonged thrombocytopenia complicated by bleeding episodes represent a major problem following autologous bone marrow transplantation (ABMT). Recombinant human interleukin-6 (rhIL-6) has been shown to be a maturation factor for both mouse and human megakaryocytes. We administered rhIL-6 to a 43 year old woman who developed marked resistant and prolonged thrombocytopenia with bleeding episodes following autologous peripheral blood stem cell transplantation (APBSCT). Twenty days after the initiation of rhIL-6 therapy, the number of megakaryocyte (MK) progenitors (CFU-MK and BFU-MK) cultured from the peripheral blood increased followed by a moderate increase in the number of bone marrow megakaryocytes. The platelet count increased and the bleeding episodes disappeared. Although spontaneous platelet recovery cannot be ruled out in this case it seems that rhIL-6 may be an important thrombopoietic factor for severe thrombocytopenia following APBSCT.

Original languageEnglish
Pages (from-to)343-349
Number of pages7
JournalLeukemia and Lymphoma
Volume19
Issue number3-4
DOIs
StatePublished - 1995
Externally publishedYes

Keywords

  • In-vitro megakaryotopoiesis
  • Interleukin 6
  • RIL-6

Fingerprint

Dive into the research topics of 'Recombinant human interleukin-6 accelerates in-virto megakaryocytopoiesis and platelet recovery post autologous peripheral blood stem cell transplantion'. Together they form a unique fingerprint.

Cite this